Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables

France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables


Overview

  • France bioprocessing tech firm's H1 revenue rose 2.5%, or 6.4% in constant currencies

  • Underlying EBITDA for H1 increased 3.7%, margin rose to 31.4%

  • Company confirms 2026 guidance for sales revenue growth of 6-10% in constant currencies


Outlook

  • Sartorius Stedim Biotech expects 2026 sales revenue growth of 6% to 10% in constant currencies

  • Company says customer compensation for U.S. tariffs could reduce revenue by up to EUR 35 mln

  • Sartorius Stedim Biotech projects 2026 underlying EBITDA margin to increase to slightly above 31%


Result Drivers

  • RECURRING CONSUMABLES - Co said recurring business with consumables was the main driver of H1 growth across all regions

  • TARIFF REFUNDS - H1 results were influenced by U.S. tariff refunds and compensation to customers, which had a technical impact on reported revenue

  • ASIA/PACIFIC RECOVERY - Strong growth in Asia/Pacific region supported by continued recovery in China


Company press release: ID:nEQ52W4WYa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Adjusted EBITDA

EUR 478.90 mln

H1 Operating Income

EUR 303.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Sartorius Stedim Biotech SA is €227.50, about 29.8% above its July 22 closing price of €175.30

  • The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 31 three months ago


Reuters Recommended Reads

  • July 22 - Switzerland's Lonza H1 sales rise, lifts FY core EBITDA margin forecast

  • July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

  • July 22 - Repligen beefs up cell therapy business with $1.5 billion deal for BioLife


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Sartorius Stedim Biotech SA

See all news